Preoperative Chemoradiotherapy for Resectable Gastric Cancer
In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in...
Pembrolizumab in HER2-Positive Gastric Cancer
The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and...
NEJM at ESMO — Preoperative Chemoradiotherapy for Resectable Gastric Cancer
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of...
Preoperative Chemoradiotherapy for Resectable Gastric Cancer
In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in...
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Among patients with limited-stage small-cell lung cancer, overall and progression-free survival were significantly longer with durvalumab adjuvant therapy added to standard concurrent chemoradiotherapy.
The New...
